Share Price, page-10932

It is possible existing institutional holders may buy back in at the next catalysts (or before) if a) there are changes in their portfolio balance that allow it without exceeding mandated limits or b) inflows into FUM of their fund increases making room to increase their holding without exceeding mandated limits.

There are other risk management rules that may compel an institution to sell that I didn't mention in my post above. One that is particularly relevant to biotech is that a fund may not wish to, or is compelled not to, carry a full size position across a binary risk event such as a clinical trial readout or regulatory decision.